Presentation is loading. Please wait.

Presentation is loading. Please wait.

Volume 381, Issue 9875, Pages (April 2013)

Similar presentations


Presentation on theme: "Volume 381, Issue 9875, Pages (April 2013)"— Presentation transcript:

1 Volume 381, Issue 9875, Pages 1391-1403 (April 2013)
Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial  The Lancet  Volume 381, Issue 9875, Pages (April 2013) DOI: /S (12) Copyright © 2013 Elsevier Ltd Terms and Conditions

2 Figure 1 Trial profile Study ended on March 16, ART=antiretroviral therapy. *Predominant reason for ineligibility given according to frequency. † First randomisation included, second excluded. ‡Communication error at enrolment. §Both on intensive phase of tuberculosis treatment. The Lancet  , DOI: ( /S (12) ) Copyright © 2013 Elsevier Ltd Terms and Conditions

3 Figure 2 Substitution in first-line ART (any reason) and switch to second-line ART (A) By monitoring strategy. (B) By ART strategy. Lines show cumulative incidence of switch to second-line treatment before death on first-line, and of substitution in first-line before death on first-line estimated treating death on first-line as a competing risk. ART=antiretroviral therapy. CHR=cause-specific hazard ratio. CDM=clinically driven monitoring. LCM=laboratory and clinical monitoring. The Lancet  , DOI: ( /S (12) ) Copyright © 2013 Elsevier Ltd Terms and Conditions

4 Figure 3 New WHO 4 stage event or death (A), CD4 (B), viral load (C), and adverse events (D), by monitoring strategy CDM=clinically driven monitoring. LCM=laboratory and clinical monitoring. ART=antiretroviral therapy. AE=adverse event. SAE=serious adverse event. *CD4 cell count in children aged 5 years or older at ART initiation. † Upper lines show suppression less than 400 copies per mL and lower lines suppression less than 80 copies per mL (2:1 dilution used for most samples because of low stored volumes). The Lancet  , DOI: ( /S (12) ) Copyright © 2013 Elsevier Ltd Terms and Conditions

5 Figure 4 New WHO 4 stage event or death (A), CD4 (B), viral load (C), and adverse events (D), by ART strategy ART=antiretroviral therapy. AE=adverse event. SAE=serious adverse event. *CD4 cell count in children aged 5 years or older at ART initiation. † Upper lines show suppression less than 400 copies per mL and lower lines suppression less than 80 copies per mL (2:1 dilution used for most samples because of low stored volumes). The Lancet  , DOI: ( /S (12) ) Copyright © 2013 Elsevier Ltd Terms and Conditions


Download ppt "Volume 381, Issue 9875, Pages (April 2013)"

Similar presentations


Ads by Google